Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
See the detailed breakdowns below
Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Start with 50-100 mg IV hydrocortisone Q6hr (depending on severity)
With multiple dosing, tirzepatide accumulates approximately 1.7-fold, meaning steady-state levels are about 70% higher than what a single dose would produce
Reta products are supplied strictly for laboratory and scientific research purposes only
US$ 29.57
US$ 22.97
US$ 24.15
US$ 22.90
